Press Release Arcutis to Report Second Quarter 2026 Financial Results and Host Conference Call on August 5, 2026 Jul 15
Press Release FDA Accepts Supplemental New Drug Application for Arcutis’ ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Infants Down to 3 Months Jul 8